Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy

Open access
Travis, Lois B., Ng, Andrea K., Allan, James M., Pui, Ching-Hon, Kennedy, Ann R., Xu, X. George, Purdy, James A., Applegate, Kimberly, Yahalom, Joachim, Constine, Louis S., Gilbert, Ethel S., Boice, John D.·2012·JNCI: Journal of the National Cancer Institute

Abstract

Advances in cancer therapy, early detection, and supportive care have contributed to steady gains in the 5-year relative survival rate for all cancers combined, which reached 66.0% for patients diagnosed during 1999-2006 (1).Commensurately, the number of cancer survivors in the United States has tripled since 1971 and is growing by 2% each year.As of 2007, there were approximately 12 million men and women in the United States-approximately 3.5% of the US population-with a history of cancer (1).For many patients, these gains in survival have come at the price of serious treatment-associated late adverse effects.Radiation remains a cornerstone of successful cancer treatment, with 50% of all patients estimated to receive radiotherapy (2).Second malignant neoplasms (SMNs) and cardiovascular disease (CVD) are two of the most frequent and important life-threatening adverse events associated with radiotherapy.Multiple primary cancers now account for approximately one in six of all incident cancers reported to the US Surveillance, Epidemiology, and End Results Program cancer registry (1).For patients with Hodgkin lymphoma (3), testicular cancer (4,5), and certain childhood cancers (6), SMNs have emerged as an important cause of death (7).Radiotherapy-associated CVD refers to a wide spectrum of disorders and is an important cause of morbidity and mortality, most notably after thoracic radiotherapy for Hodgkin lymphoma and tangential radiotherapy for breast cancer (8,9).With the increased awareness of the adverse consequences of cancer therapy, it has become critically important to identify measures to mitigate and ameliorate these late adverse effects and to provide cancer survivors with counseling, surveillance, and supportive care.In addition, it is essential to review and balance the risks and benefits of new treatment options as they become available.Providing a research infrastructure for transdisciplinary studies of cancer survivors is also important (10).The Childhood Cancer Survivorship Study (CCSS) is a critical resource for outcome and intervention research in survivors of pediatric and adolescent cancer (11); however, a comparable research base is lacking for survivors of young adult-onset (12,13) and other cancers.The expanding use of radiotherapy and development of new radiation modalities to treat cancer, coupled with improvements in longterm patient survival, underscores the importance of continuing to provide long-term risk estimates as well as additional research into the molecular underpinnings of treatment-related SMNs and CVD.Moreover, optimal screening and interventional efforts for these late adverse events must be identified (5).To review and address the expanding burden of late adverse effects after treatment with radiation, the National Council on

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djr533

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 229

Metadata

Authors
Travis, L. B., Ng, A. K., Allan, J. M., Pui, C.-H., Kennedy, A. R., Xu, X. G., Purdy, J. A., Applegate, K., Yahalom, J., Constine, L. S., Gilbert, E. S., & Boice, J. D.
Venue
JNCI: Journal of the National Cancer Institute
Published
2012-02-06
Volume
104
Issue
5
Pages
357-370
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2147498149
Cited by
229
References
4
FWCI
16.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. https://app.cochat.ai/papers/10.1093/jnci/djr533
The paper
Travis, L. B., Ng, A. K., Allan, J. M., Pui, C.-H., Kennedy, A. R., Xu, X. G., Purdy, J. A., Applegate, K., Yahalom, J., Constine, L. S., Gilbert, E. S., & Boice, J. D. (2012). Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djr533

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.